AUNA

Interested in Auna S.A.? Here are five stocks we like better. Auna’s revenue grew 9% year over year on an FX-neutral basis, driven by higher patient volumes and a greater mix of complex services, but adjusted EBITDA fell 9% amid margin pressure, talent investments and Peru billing penalties. Mexico patient volumes recovered, with sequential increases in surgeries and oncology treatments, while Colombia revenue rose 13% as the company expanded private-payer and risk-sharing contracts. Peru revenue increased 8%, though EBITDA was held flat by billing-related penalties and higher operating costs. Cash generation and leverage improved significantly: first-half operating cash flow rose 45%, free cash flow increased 181% and leverage declined to 3.6 times. Auna reaffirmed its outlook for roughly 12% FX-neutral revenue growth and adjusted EBITDA growth near the low end of its 10%-14% target range. Auna (NYSE:AUNA) reported second-quarter results marked by continued revenue growth, improving cash generation and a sequential recovery in patient volumes in Mexico, though adjusted EBITDA declined amid margin pressures, talent investments and billing-related penalties in Peru. Executive Chairman and President Suso Zamora said consolidated revenue increased 9% year over year on an FX-neutral basis, driven by higher volumes and a greater mix of high-complexity services across Mexico, Peru and Colombia. Consolidated adjusted EBITDA declined 9%, reflecting temporary pressure in Mexico and Colombia and accepted penalties tied primarily to the reconciliation of prior-year receivables in Peru. → Looking Beyond CrowdStrike? 3 AI Security Stocks Stand Out “Despite encountering margin pressures across each of our markets during the quarter, the underlying performance of the business remains robust,” Zamora said, citing continued demand across the company’s regional healthcare platform. Mexico showed an accelerating recovery in patient volumes during the quarter. Surgeries rose 7% sequentially, while oncology chemotherapies and radiotherapies increased 20% from the first quarter. On a year-over-year basis, surgery volumes increased 6% and chemotherapy and radiotherapy volumes grew 86%, according to Chief Financial Officer and Executive Vice President Gisele Remy. → 3 Robotics Stocks Under $10: Value, Momentum, or Bet? The company attributed the recovery to improved tier classifications with major insurers, expansion of oncology services, physician onboarding and productivity, and favorable pricing in high-complexity care. A new ISSSTE León government contract, surgical and hemodynamics packages, and out-of-pocket revenue also contributed. Mexico revenue increased 4% year over year and 5% sequentially. Adjusted EBITDA rose 3% sequentially but declined 16% from a year earlier, primarily because of continued investment in medical and leadership talent. Zamora said April’s Easter holidays and Mexico’s new value-added tax on insurance affected the quarter, though volumes and revenue increased noticeably in May and June. → Michael Burry Is Betting Against Palantir Again—Should Investors Care? Auna said it expects stronger year-over-year growth in Mexico in the second half as high-productivity physicians are added and high-complexity services continue expanding. The company also plans to inaugurate an Elekta Evo linear accelerator in September. Peru revenue rose 8%, supported by higher average ticket sizes, membership growth and greater penetration of the business-to-business market. Oncosalud revenue increased 11%, helped by annual price adjustments, service mix improvements and a 6% increase in memberships. Membership expansion included a new B2B plan covering 7,000 Serpal employees. Commercial initiatives also drove a 9% year-over-year increase in emergency treatments, while capacity utilization reached 83%. Despite the top-line growth, Peru adjusted EBITDA was flat year over year. The company cited accepted penalties related to billing matters, primarily involving prior-year receivables reconciliations, as well as B2B onboarding costs, physician retention incentives, overtime and pharmacy expenses. Remy said financial pressure among Peruvian payers had led to stricter enforcement of billing deadlines and settlement terms. Auna is shortening its billing cycle and strengthening financial controls, and it expects to finalize open negotiations involving prior-year billing matters during 2026. After the quarter ended, Auna took possession of a facility that will expand capacity in southern Lima. The project is expected to add 30 beds and expand surgery and chemotherapy capacity, with operations expected between late 2027 and early 2028. The company also acquired a Versius SP4 robotic system for minimally invasive procedures. Colombia revenue increased 13%, supported by private-payer relationships and risk-sharing agreements. Risk-sharing contracts represented 24% of Colombian revenue, up from 14% a year earlier, and covered more than 3 million lives. Revenue from private payers grew 17% and represented 18% of Colombia’s quarterly revenue. At the same time, revenue from intervening payers fell to 12% from 18% a year earlier. Capacity utilization rose to 79.2%, exceeding levels seen before the Nueva EPS intervention, the company said. Colombian adjusted EBITDA declined 12% year over year due to higher costs associated with more complex care, statutory wage increases, talent investments and the growing risk-sharing contract mix. However, adjusted EBITDA increased 18% sequentially, and margins expanded by 1.7 percentage points. Auna expects contractual price increases in the second half to offset much of the cost pressure. Following the quarter, the company expanded capacity at IMAT Oncomédica facilities in Montería by adding 18 adult intensive-care beds and 24 hospitalization beds, which it said required minimal additional capital spending. Adjusted net income was PEN 40 million in the second quarter. Remy said the year-over-year change was affected by a PEN 61 million decline in foreign-exchange gains after the company reset the levels of FX hedges related to debt at the end of 2025. Net cash from operating activities reached PEN 441 million for the first half, up 45% year over year, while free cash flow rose 181%. Auna attributed the improvement to working-capital management, collection recoveries, supply-chain financing initiatives and the use of tax credits. Cash increased 43% from year-end 2025, while leverage declined to 3.6 times from the first quarter. The company reaffirmed its full-year outlook for approximately 12% FX-neutral revenue growth. It expects adjusted EBITDA growth toward the low end of its 10% to 14% target range, excluding the impact of accepted billing penalties in Peru. Management also expects leverage to continue declining toward its medium-term target of less than three times net debt to adjusted EBITDA. Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna's organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints. The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Auna Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Consolidated revenue growth of 9% was driven by a strategic shift toward high-complexity services, including a 20% sequential increase in oncology treatments in Mexico. Adjusted EBITDA declined 9% due to temporary margin pressures from investments in medical leadership talent in Mexico and billing reconciliation penalties in Peru. In Mexico, the company successfully secured improved tier classifications with major insurers, which accelerated patient volume recovery following operational enhancements implemented last year. The Colombia segment demonstrated a successful pivot in payer mix, with risk-sharing agreements now representing 24% of revenue, up from 14% a year ago, enhancing cash predictability. Peru's performance was bolstered by a 6% expansion in memberships, including a significant new B2B contract for 7,000 employees, despite onboarding costs impacting short-term profitability. Management attributed the 181% increase in free cash flow to disciplined working capital management, improved collections in Colombia, and the strategic use of supply chain financing. Management reaffirmed full-year 2026 revenue guidance of approximately 12% FX-neutral growth, supported by strong volume recovery trends in Mexico. Adjusted EBITDA growth is expected at the low end of the 10% to 14% range, excluding the impact of one-time billing penalties in Peru. The company expects to reach its medium-term leverage target of less than 3x net debt to EBITDA by the end of the year, driven by sequential EBITDA improvements and robust cash generation. Strategic capacity expansion is underway with a new clinical facility in Lima Sur expected to be operational by late 2027 or early 2028 using an asset-light model. Profitability in Colombia is projected to improve in the second half of 2026 as contractual price increases take full effect to offset statutory wage hikes and talent investments. Accepted billing penalties in Peru related to prior-year receivables reconciliation impacted quarterly EBITDA; management expects to finalize all such legacy negotiations within 2026. Mexico's quarterly growth was partially tempered by the timing of Easter holidays and the implementation of a new value-added tax on insurance. Auna is selectively resuming growth capital investments in Colombia following the government's emergency stabilization plan, focusing on capital-efficient capacity additions like the new ICU beds in Monteria. Foreign exchange gains decreased by PEN 61 million year-over-year following a strategic reset of FX hedges at the end of 2025 to reduce future volatility. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed that improvements in accounts receivable days are sustainable due to shortened internal billing cycles and a higher mix of faster-paying risk-sharing contracts. Supplier financing initiatives have successfully extended payable days without negatively impacting the underlying cost structure or margins. The cash flow benefit also included the strategic utilization of VAT credits, particularly in the Peruvian market. The increase in penalties reflects a sector-wide trend where Peruvian payers are tightening enforcement of billing deadlines due to their own financial pressures. Auna has implemented a 'no tolerance' internal hurdle for service delivery and billing accuracy to eliminate future penalty exposure. Management views the 2026 adjustments as a 'reset' and expressed confidence that these retrospective reconciliations will not persist into 2027.

This article first appeared on GuruFocus. Release Date: August 19, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Consolidated revenue grew 9% year-over-year, driven by volume growth and a better mix of high-complexity services across all markets. Mexico showed strong sequential recovery, with surgeries up 7% and oncology treatments up 20% versus Q1 2026. Peru's Oncosalud revenue increased 11%, supported by a 6% membership growth and a new B2B plan covering 7,000 employees. Colombia's adjusted EBITDA improved 18% sequentially, with capacity utilization rising to 79.2% and risk-sharing contracts now covering over 3 million lives. Free cash flow surged 181% year-over-year, and cash position grew 43% since year-end 2025, reflecting strong working capital management. Leverage improved to 3.6 times net debt to EBITDA, with expectations to move closer to the 3 times target by year-end. The company reaffirmed its full-year 2026 revenue guidance of approximately 12% FX-neutral growth. Consolidated adjusted EBITDA declined 9% on an FX-neutral basis, impacted by margin pressures in Mexico and Colombia and billing penalties in Peru. Mexico's adjusted EBITDA fell 16% year-over-year due to continued investments in medical and leadership talent, plus the impact of Easter holidays and a new VAT on insurance. Peru's adjusted EBITDA was flat, affected by accepted penalties related to prior-year billing reconciliations and higher B2B onboarding costs. Colombia's adjusted EBITDA decreased 12% year-over-year, reflecting higher costs from greater complexity, minimum wage increases, and the growing mix of risk-sharing agreements. Adjusted net income was impacted by a $61 million decrease in FX gains due to resetting FX hedges at the end of 2025. The company expects adjusted EBITDA growth to be at the low end of its 10%-14% guidance range, excluding the impact of Peru's billing penalties. Warning! GuruFocus has detected 5 Warning Signs with AUNA. Is AUNA fairly valued? Test your thesis with our free DCF calculator. Q: How much of the working capital improvement came from ordinary payment timing versus supplier financing or other mechanisms, and what is the underlying cash conversion if adjusted for these programs? A: Giselle Rami, CFO and Executive Vice President, explained that the majority of the improvement on the accounts receivable side is due to reduced billing cycles, particularly in Colombia and Peru, and a higher proportion of faster-paying risk-sharing contracts. The accounts payable gains are attributed to sustainable supply chain financing initiatives with financial institutions. She clarified that these improvements are sustainable and do not require adjustments, with working capital also benefiting from VAT credits in Peru. Q: Have you changed the methodology and controls to estimate expected payer deductions in Peru, and what evidence gives confidence that the 2026 receivables vintage will not require similar retrospective adjustments? A: CFO Giselle Rami acknowledged higher billing penalties in Peru due to sector-wide financial pressure on payers tightening enforcement. She stated that Auna is actively shortening internal billing cycles and strengthening financial controls to eliminate future exposure. All open negotiations related to prior-year billing matters are expected to be finalized during 2026, making this a short-term impact. Executive Chairman Tuso Zamora added that the company has implemented a "zero tolerance" approach to service delivery and payment discussions, fundamentally changing the entire service and collection cycle. Q: Does the supplier financing benefit come at the expense of cost, explaining the margin impact? A: CFO Giselle Rami confirmed that the supply chain financing initiatives do not impact the cost structure, as they were the result of close negotiations and onboarding with suppliers. Q: What drove the consolidated revenue growth and adjusted EBITDA decline in Q2 2026? A: Executive Chairman Tuso Zamora reported a 9% increase in consolidated revenue, driven by volume growth and a better mix of higher-complexity services across Mexico, Peru, and Colombia. However, consolidated adjusted EBITDA decreased 9% on an FX-neutral basis due to temporary margin pressures in Mexico and Colombia, as well as accepted penalties related to billing reconciliations of prior years' receivables in Peru. Q: What is driving the recovery in Mexico, and what are the expectations for the second half of the year? A: Tuso Zamora highlighted that Mexico's recovery accelerated, with surgeries increasing 7% and oncology chemotherapies/radiotherapies increasing 20% sequentially. This was attributed to improved tier classifications with major insurers and expanded oncology offerings. Despite a 16% year-over-year adjusted EBITDA decline due to talent investments, the company expects stronger year-over-year growth in the latter half, supported by a noticeable volume and revenue increase in May and June. Q: What are the key drivers of Peru's performance and the outlook for profitability? A: Tuso Zamora noted that Peru achieved 8% revenue growth, driven by higher average tickets, 6% membership expansion, and a new B2B plan covering 7,000 Serapal employees. Adjusted EBITDA was flat year-over-year due to billing penalties and higher B2B onboarding costs, physician retention incentives, and pharmacy costs. The company expects profitability to improve as onboarding costs normalize, with a new clinical facility in south Lima expected to become operational between end-2027 and early 2028. Q: How is Colombia's diversification strategy progressing, and what is the margin outlook? A: Tuso Zamora reported that risk-sharing agreements now constitute 24% of Colombia's revenue, up from 14% a year ago, covering over 3 million lives. Intervened payers declined to 12% of revenue from 18%. While adjusted EBITDA declined 12% year-over-year due to higher complexity costs and wage increases, it improved 18% sequentially. The company anticipates contractual price increases in the second half to largely offset cost pressures and support stronger EBITDA growth. Q: What is the company's leverage and cash flow position, and what are the expectations for the remainder of 2026? A: CFO Giselle Rami stated that leverage decreased to 3.6 times from Q1 2026, supported by strong cash generation. Cash increased 43% against year-end 2025, and free cash flow grew 181% year-over-year. The company expects leverage to continue improving by year-end, moving closer to the medium-term target of 3 times net debt to EBITDA. Gross debt fell by $43 million on an FX-neutral basis, with 56% of debt in local currency and 85% of USD debt hedged to the Peruvian sol. Q: What is the full-year 2026 guidance, and how are the billing penalties impacting it? A: Tuso Zamora reaffirmed full-year 2026 revenue guidance of approximately 12% FX-neutral growth. Adjusted EBITDA growth is expected toward the low end of the 10% to 14% guidance range, excluding the impact of Peru's accepted billing penalties. The company expects continued leverage reduction and free cash flow to exceed original expectations, supported by a strong recovery in Mexico and operational improvements in Colombia. Q: What strategic investments are being made to support growth? A: Tuso Zamora highlighted several investments, including an Elekta EVO linear accelerator in Monterrey, Mexico, a Versys FP4 robotic system in Peru, expanded capacity at EMAX Oncomedica facilities in Monteria, Colombia (18 adult ICU beds and 24 hospitalization beds), and a new clinical facility in south Lima. These investments are expected to be accretive to the company's competitive advantage and support high-complexity care growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

A consecutive quarter of strong top-line growth and cash flow performance;Consolidated Adjusted EBITDA impacted by service mix across the segments LUXEMBOURG, August 18, 2026--(BUSINESS WIRE)--Auna (NYSE: AUNA) ("Auna" or the "Company"), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the second quarter ended June 30, 2026 ("Second quarter 2026" or "2Q26"). Financial results are expressed in Peruvian Soles ("S/" or "PEN" or "Soles") and are presented in accordance with International Financial Reporting Standards ("IFRS"), unless otherwise noted. 2Q’26 Consolidated Highlights Revenue increased 9% FXN, or 13% YoY on a reported basis, to S/1,238 million Adjusted EBITDA was S/227 million, a decrease of 9% YoY FXN or 6% YoY on a reported basis, and an increase of 3% FXN from 1Q26 Adjusted EBITDA Margin of 18.4%, slightly up from 1Q26 Operating Cash Flow and Free Cash Flow increased 45% YoY and 181% YoY, respectively Leverage Ratio improved to 3.6x Oncology MLR remained stable at 50.1% Number of surgeries increased 5.2% YoY to 21,912 Number of days hospitalized increased 5% YoY to 135,107 Number of chemotherapy and radiotherapy sessions increased 15% YoY Message from Auna’s Executive Chairman and President The second quarter of 2026 demonstrated sustained commercial momentum across our markets and progress in the operational initiatives that support our growth strategy. Revenue increased by 9% FXN, while Adjusted EBITDA declined 9% FXN. This reflects service mix and temporary margin pressure in Mexico and Colombia, as well as pharmacy and payroll costs, along with the impact of accepted penalties primarily related to billing matters in the reconciliation of prior years' receivables in Peru. In Peru, our integrated model continues to deliver strong results, Peru achieved an 8% revenue growth, driven by new B2B memberships at Oncosalud and increased volumes in high-complexity procedures within our healthcare network. Oncosalud expanded its B2B membership base, while higher occupancy in the healthcare network underscored our focus on growing in high complexity. Adjusted EBITDA reflects increased pharmacy, physician and payroll expenses required to accommodate the surge in patient volumes, as well as accepted penalties primarily attributable to previous years’ billing matters. In Mexico, patient volume recovery continued throughout the quarter. Improved tier classifications with key payors, improved pricing for high-complexity services, and the ongoing expansion of our oncology offering contributed to stronger volumes, particularly in June. This momentum drove 4% year-over-year revenue growth in local currency, while revenue and Adjusted EBITDA increased by 5% and 3%, respectively, compared to the first quarter of 2026, in local currency. Although service mix and talent investments continued to affect margins year over year, both Adjusted EBITDA and margin improved sequentially, indicating progress in the initiatives underway in Monterrey and positioning the network for sustained volume growth in the second half. In Colombia, revenue increased by 13% in local currency, primarily due to the sustained expansion of risk-sharing ("PGP") contracts, which accounted for 24% of segment revenue. Additionally, reduced exposure to intervened payors, which constituted 12% of revenue, and enhanced payment agreements contributed to the strengthening of the quality and predictability of our payor mix. First-half margins reflected the variable costs of stabilizing our new PGP contracts, alongside statutory wage increases and planned SG&A investments. Contractual price adjustments scheduled for the second half of the year are expected to drive improved profitability in the coming quarters. Consolidated Cash flow generation continued to be a key highlight in the second quarter of 2026. Operating cash flow increased by 45% year-over-year, while free cash flow grew by 181%, driven by disciplined working capital management and improved payor collections. Despite initial margin pressure, our leverage ratio improved to 3.6x, underscoring the resilience of our business model and supporting our progress toward a medium-term target of below 3.0x. The recent elections in Peru and Colombia have so far generally been viewed as a positive development for private-sector participation and long-term healthcare investment. This could create a more favorable environment for our industry and provides greater visibility into our strategic path forward. Looking ahead, given the recovery in volumes in Mexico and our projected performance for the remainder of the year, we reaffirm our full-year 2026 revenue guidance. We anticipate revenue growth near the midpoint of our 10% to 14% FX-neutral range, or approximately 12%. We expect Adjusted EBITDA growth toward the low end of that range, reflecting temporary cost pressures across our three geographies as the business scales. The Adjusted EBITDA outlook excludes the impacts of accepted penalties primarily related to billing matters in the reconciliation of prior years' receivables in Peru. Capital expenditures guidance remains unchanged at approximately 4% of revenues. Although we did not provide formal free cash flow guidance, we expect it to exceed our original internal expectations, supported by strong working capital management and improved collections, further supporting our deleveraging path. Overview of 2Q26 Consolidated Results Revenues in 2Q26 increased 9% FXN and 13% YoY on a reported basis to S/1,238 million, with revenues in local currency ("LC") increasing across all segments: 4% in Mexico, 8% in Peru and 13% in Colombia. In Mexico, the Healthcare network sustained higher surgery and oncology volumes, reflecting the continued benefits of the improved tier classifications with key payors implemented in prior periods, as well as growth in packages and out-of-pocket revenues. In Peru, Oncosalud increased revenues through additional B2B memberships, while the healthcare network benefited from higher volumes of high-complexity surgeries. In Colombia, volumes continued to grow across PGP services in cardiovascular, ambulatory and oncology care, supported by the ongoing scaling of risk-sharing models and diversification away from intervened payors. Adjusted EBITDA in 2Q26 decreased 9% FXN, or 6% YoY on a reported basis, to S/227 million, with an Adjusted EBITDA Margin of 18.4%. In LC, Segment Adjusted EBITDA decreased 16% in Mexico and 12% in Colombia, while remaining flat in Peru. In Mexico, Segment Adjusted EBITDA decreased versus 2Q25, due to a lower contribution margin from the current mix of services and specialties, as well as higher SG&A expenses related to talent investments that impacted payroll. On a sequential basis, however, Segment Adjusted EBITDA grew 3% versus 1Q26 mostly from improved gross profit. Consolidated Peru Adjusted EBITDA growth was impacted by accepted penalties primarily related to billing matters in the reconciliation of prior years' receivables and by pharmacy and medical talent costs related to supporting increased patient volumes at the healthcare network and Oncosalud. In Colombia, Segment Adjusted EBITDA sustained a strong top line, partially offset by lower margins from a higher proportion of PGP contracts and from increased oncology services. Reported results were impacted by foreign exchange fluctuations, specifically, a 5% appreciation of the Mexican Peso ("MXN") and a 9% appreciation of the Colombian Peso ("COP") against the PEN. Net finance costs for 2Q26 were S/105 million, compared to S/46 million in 2Q25. Excluding foreign exchange effects, net finance costs totaled S/113 million in 2Q26, compared to S/115 million in 2Q25, reflecting a YoY decrease of S/2 million, or 1%. When also excluding the non-cash impact related to the future purchase obligation for IMAT Oncomedica, which began affecting finance expenses in 3Q25, net finance costs decreased by S/4 million. The increase in reported net finance costs primarily reflected lower non-cash FX gain of S/8 million, compared to a non-cash gain of S/68 million in 2Q25. Net Income for 2Q26 was S/33 million compared to S/84 million in 2Q25. The decline was primarily driven by a S/61 million decrease in positive non-cash FX impact on net finance costs compared to the prior-year period. On a per-share basis, Net Income was S/0.40, based on a weighted average of 74,237,368 basic and diluted shares. Adjusted Net Income for 2Q26 was S/40 million, compared to S/89 million in 2Q25. The decline reflects the same FX-driven variance on the net finance costs described above. As mentioned in previous quarters, the FX volatility has been reduced by resetting the levels on USD PEN hedges after the refinancing exercise at the end of 2025. On a per-share basis, Adjusted Net Income was S/0.50, based on a weighted average of 74,237,368 basic and diluted shares. For a full version of AUNA’s Second Quarter 2026 Earnings Release, please visit:https://aunainvestors.com/English/financial-information/quarterly-results/ Conference Call Details When: 8:00 a.m. Eastern time, August 19, 2026 Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets. Dial-in: +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International)Passcode: 3884034 To access Auna′s financial results call via telephone, callers need to press # to be connected to an operator. Webcast: click here About AUNA Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of June 30, 2026, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,337 beds, and 1.5 million healthcare plans. For more information visit www.aunainvestors.com. Safe Harbor Statement This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "project," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the execution of our strategic plan, including the recovery of our growth levels and the roll-out of the AunaWay in Mexico, our planned investments, our revenue, Adjusted EBITDA and capital expenditure guidance, our expectation for revenue and Adjusted EBITDA growth, policy expectations regarding the newly elected administrations in Colombia and Peru, expectations for the Elekta EVO linear accelerator to become operational, mobilization of Auna Lima Sur and the creation of further growth and sustainable value for all stakeholders. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors. The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the "SEC"). Financial Guidance Disclaimer Auna′s guidance is based on management’s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided. Auna’s financial guidance reflects management’s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company’s Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the Leverage Ratio target and Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the "Safe Harbor Statement" section in this release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818121546/en/ Contacts IR Contact Email: [email protected]

Auna S.A. (AUNA) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -42.31%. A quarter ago, it was expected that this company would post earnings of $0.19 per share when it actually produced earnings of $0.05, delivering a surprise of -73.68%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Auna S.A., which belongs to the Zacks Medical Services industry, posted revenues of $363 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.16%. This compares to year-ago revenues of $309 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Auna S.A. shares have added about 9.4% since the beginning of the year versus the S&P 500's gain of 13.1%. While Auna S.A. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Auna S.A. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.27 on $362.63 million in revenues for the coming quarter and $0.79 on $1.46 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. InnovAge Holding Corp. (INNV), another stock in the same industry, has yet to report results for the quarter ended June 2026. This company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +800%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. InnovAge Holding Corp.'s revenues are expected to be $234.17 million, up 5.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Auna S.A. (AUNA) : Free Stock Analysis Report InnovAge Holding Corp. (INNV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Wall Street expects a year-over-year decline in earnings on higher revenues when Auna S.A. (AUNA) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 18. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -21.2%. Revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Auna S.A., the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +9.80%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Auna S.A. will most likely beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Auna S.A. would post earnings of $0.19 per share when it actually produced earnings of $0.05, delivering a surprise of -73.68%. Over the last four quarters, the company has beaten consensus EPS estimates three times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Auna S.A. appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Surgery Partners (SGRY) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +400.00%. A quarter ago, it was expected that this surgical facilities operator would post a loss of $0.15 per share when it actually produced a loss of $0.03, delivering a surprise of +80%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Surgery Partners, which belongs to the Zacks Medical Services industry, posted revenues of $848.9 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.62%. This compares to year-ago revenues of $826.2 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Surgery Partners shares have added about 0.5% since the beginning of the year versus the S&P 500's gain of 13.3%. While Surgery Partners has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Surgery Partners was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.06 on $851.78 million in revenues for the coming quarter and $0.36 on $3.41 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Auna S.A. (AUNA), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 18. This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -21.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Surgery Partners, Inc. (SGRY) : Free Stock Analysis Report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Progyny (PGNY) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.84%. A quarter ago, it was expected that this provider of fertility and family building benefits would post earnings of $0.44 per share when it actually produced earnings of $0.5, delivering a surprise of +13.64%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Progyny, which belongs to the Zacks Medical Services industry, posted revenues of $350.51 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.38%. This compares to year-ago revenues of $332.87 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Progyny shares have added about 22.2% since the beginning of the year versus the S&P 500's gain of 12.8%. While Progyny has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Progyny was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.52 on $352.05 million in revenues for the coming quarter and $2.04 on $1.38 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Auna S.A. (AUNA), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 18. This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -21.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Progyny, Inc. (PGNY) : Free Stock Analysis Report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Solventum (SOLV) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +33.51%. A quarter ago, it was expected that this health care company would post earnings of $1.35 per share when it actually produced earnings of $1.48, delivering a surprise of +9.63%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Solventum, which belongs to the Zacks Medical Services industry, posted revenues of $2.21 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.03%. This compares to year-ago revenues of $2.16 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Solventum shares have added about 11% since the beginning of the year versus the S&P 500's gain of 13%. While Solventum has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Solventum was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.44 on $2 billion in revenues for the coming quarter and $6.58 on $8.22 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Auna S.A. (AUNA), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 18. This company is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -21.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Solventum Corporation (SOLV) : Free Stock Analysis Report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +14.63%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.02 per share when it actually produced earnings of $1.06, delivering a surprise of +3.92%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Revvity, which belongs to the Zacks Medical Services industry, posted revenues of $729.69 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.57%. This compares to year-ago revenues of $720.28 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Revvity shares have added about 19.1% since the beginning of the year versus the S&P 500's gain of 11%. While Revvity has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Revvity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.30 on $678.78 million in revenues for the coming quarter and $5.25 on $2.84 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Auna S.A. (AUNA), is yet to report results for the quarter ended June 2026. The results are expected to be released on August 18. This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -27.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Revvity Inc. (RVTY) : Free Stock Analysis Report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +10.53%. A quarter ago, it was expected that this company would post earnings of $0.16 per share when it actually produced earnings of $0.17, delivering a surprise of +6.25%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Avantor, which belongs to the Zacks Medical Services industry, posted revenues of $1.69 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.17%. This compares to year-ago revenues of $1.68 billion. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Avantor shares have added about 8.4% since the beginning of the year versus the S&P 500's gain of 8.5%. While Avantor has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Avantor was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.20 on $1.62 billion in revenues for the coming quarter and $0.79 on $6.5 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Auna S.A. (AUNA), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 18. This company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -27.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Auna S.A.'s revenues are expected to be $350.52 million, up 13.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Avantor, Inc. (AVTR) : Free Stock Analysis Report Auna S.A. (AUNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research